Massive Real-World study investigates rare eye inflammation after common injection
NCT ID NCT07105228
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Researchers looked at medical records from 2017 to 2024 to identify cases and describe patient characteristics.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept (Eylea)
What this could lead to
If successful, this study could help doctors better understand the risk of retinal vasculitis in patients receiving aflibercept injections.
What could go wrong
This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Research Site
Tarrytown, New York, 10591, United States